FDA would prefer to see specific symptom assessments, rather than global evaluations of health-related quality of life, when patient-reported outcomes tools are incorporated into clinical trials for pediatric oncology treatments, agency officials told the Oncologic Drugs Advisory Committee’s pediatric oncology subcommittee Nov. 4.
During a half-day discussion on use of patient-reported outcomes (PRO) in the pediatric cancer setting, FDA officials highlighted problems with...